Home Cart Sign in  
Chemical Structure| 2243736-45-8 Chemical Structure| 2243736-45-8

Structure of FB23-2
CAS No.: 2243736-45-8

Chemical Structure| 2243736-45-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FB23-2 is a FTO inhibitor. It directly binds to FTO and selectively inhibits FTO's m6A demethylase activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FB23-2

CAS No. :2243736-45-8
Formula : C18H15Cl2N3O3
M.W : 392.24
SMILES Code : ONC(C1=CC=CC=C1NC2=C(Cl)C=C(C3=C(C)ON=C3C)C=C2Cl)=O
MDL No. :MFCD32174281
InChI Key :ILHNIWOZZKIBNW-UHFFFAOYSA-N
Pubchem ID :138454779

Safety of FB23-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P233-P260-P261-P264-P271-P280-P302+P352-P304-P304+P340-P305+P351+P338-P312-P321-P332+P313-P337+P313-P340-P362-P403-P403+P233-P405-P501

Related Pathways of FB23-2

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C666-1R cells 10 μmol 24-72 hours FB23-2 significantly sensitized NPC cells to irradiation Transl Oncol. 2023 Jan;27:101576.
Human umbilical vein endothelial cells (HUVECs) 10 μmol/L 48 hours Nicotine dose-dependently upregulated FTO and NOX2 protein abundance, which were reversed by treatment with the FTO inhibitor FB23-2 or FTO knockdown using siRNAs. Hypertension. 2024 Feb;81(2):240-251.
SiHa cells 1 µM 48 hours FB23-2 treatment significantly down-regulated intracellular DIRAS1 mRNA levels, but significantly up-regulated DIRAS1 protein levels Cancer Biol Ther. 2024 Dec 31;25(1):2306674.
C33A cells 1 µM 48 hours FB23-2 treatment significantly down-regulated intracellular DIRAS1 mRNA levels, but significantly up-regulated DIRAS1 protein levels Cancer Biol Ther. 2024 Dec 31;25(1):2306674.
HONE1R cells 10 μmol 24-72 hours FB23-2 significantly sensitized NPC cells to irradiation Transl Oncol. 2023 Jan;27:101576.
MV4-11 cells 5 μM 72 hours Determination of m6A abundance in mRNA via dot blot assay Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
ML-2 cells 5 μM 72 hours Determination of m6A abundance in mRNA via dot blot assay Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
U937 cells 5 μM 72 hours Determination of m6A abundance in mRNA via dot blot assay Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
MA9.3RAS cells 5 μM 72 hours Determination of m6A abundance in mRNA via dot blot assay Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
MA9.3ITD cells 5 μM 72 hours Determination of m6A abundance in mRNA via dot blot assay Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
MONOMAC6 cells 20 μM 72 hours Quantitation of the percentage of m6A/A and m6Am/A ratios in mRNA by LC-MS/MS Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
NB4 cells 20 μM 72 hours Quantitation of the percentage of m6A/A and m6Am/A ratios in mRNA by LC-MS/MS Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
MONOMAC6 cells 10 μM 24 hours Determination of cellular uptake of FB23-2 by LC-MS/MS quantitation Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
NB4 cells 10 μM 24 hours Determination of cellular uptake of FB23-2 by LC-MS/MS quantitation Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
Human Umbilical Vein Endothelial Cells (HUVECs) 2 µM 48 hours FB23-2 inhibits FTO's m6A demethylase activity, thereby suppressing high glucose-induced endothelial cell proliferation, migration, and tube formation. EMBO Mol Med. 2024 Feb;16(2):294-318.
Human mesenchymal stem cells (hMSCs) 2.5 µM and 5 µM 7 days To investigate the effect of FB23-2 on osteogenic differentiation of hMSCs, results showed that FB23-2 inhibited osteogenic differentiation of hMSCs. Acta Pharmacol Sin. 2022 May;43(5):1311-1323.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Not specified Intraperitoneal injection (i.p.) 20 mg/kg Daily for 14 days Examination of the toxic effects of multi-doses of FB23-2 in BALB/c mice Cancer Cell. 2019 Apr 15;35(4):677-691.e10.
Mice Oxygen-induced retinopathy (OIR) mouse model Intravenous injection 3 mg/kg Daily injection for 5 days NP-FB23-2 targets retinal neovascularization via intravenous injection, increases m6A modification levels in OIR retinas, and suppresses pathological neovascularization and endothelial tip cell formation. EMBO Mol Med. 2024 Feb;16(2):294-318.
B-NDG mice PDX model Intraperitoneal injection 8 mg/kg/day Continuously for 14 days FB23-2 inhibited tumor growth and prolonged survival Int J Biol Sci. 2022 Oct 3;18(15):5943-5962
C57BL/6J mice Experimental autoimmune uveitis (EAU) model Intravitreal injection 10 mmol/μL Single injection, lasting 5 days To investigate the effect of FB23-2 on the inflammatory response in EAU mice, results showed that FB23-2 significantly decreased retinal FTO expression and exacerbated ocular inflammation. Genes Dis. 2022 Oct 4;10(5):2179-2193
BALB/c nude mice HONE1R cell xenograft model Intraperitoneal injection 2 mg/kg Once every three days until the endpoint FB23-2 significantly delayed the growth of HONE1R xenografts and enhanced radiation sensitivity Transl Oncol. 2023 Jan;27:101576.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.75mL

2.55mL

1.27mL

25.49mL

5.10mL

2.55mL

References

 

Historical Records

Categories